| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| S-1/A | Amended Registration statement for face-amount certificate companies |
Registration Statements
|
||
| S-1/A | Amended Registration statement for face-amount certificate companies |
Registration Statements
|
||
| FWP | FWP |
Other
|
||
| S-1/A | Amended Registration statement for face-amount certificate companies |
Registration Statements
|
||
| SC 13D/A | An amendment to a SC 13D filing |
Other
|
||
| CT ORDER | CT ORDER |
Other
|
||
| S-1 | Registration statement for face-amount certificate companies |
Registration Statements
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
||
| 10-K | Annual report which provides a comprehensive overview of the company for the past year |
Annual Filings
|
EX-101.INS - XBRL INSTANCE DOCUMENT | |
| SC 13G/A | An amendment to the SC 13G filing |
Other
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
